Scholarlink

<p>Precise inter-laboratory quantitation of <i>BCR::ABL1</i> RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory reproducibility in <i>BCR::ABL1</i> quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of <i>BCR::ABL1</i> results (2009–2023) reported by over 200 clinical laboratories (6 annual samples; &gt;5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption over 7 years (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SDs of reported <i>BCR::ABL1</i> results (high-sample <i>r</i> = −0.73, <i>p</i> = 0.004; intermediate-sample <i>r</i> = −0.71, <i>p</i> = 0.022; low-sample <i>r</i> = −0.84, <i>p</i> = 0.002). IS implementation exceeded 99% by 2019, as inter-lab SD’s reached their nadir value (~0.2). No other assessed variable correlated with time-dependent improvement in inter-lab reproducibility, including reference gene selection (<i>ABL1</i> versus others), RQ-PCR reagent selection, assay type (FDA-approved, commercial, or laboratory-developed), or practice setting. IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in <i>BCR::ABL1</i> quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Annette S. Kim,
  • Thomas Long,
  • Derek A. Oldridge,
  • Lawrence J. Jennings,
  • Yi Ding,
  • Patricia Vasalos,
  • Christopher Watt,
  • Richard D. Press

摘要

Precise inter-laboratory quantitation of BCR::ABL1 RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory reproducibility in BCR::ABL1 quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of BCR::ABL1 results (2009–2023) reported by over 200 clinical laboratories (6 annual samples; >5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption over 7 years (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SDs of reported BCR::ABL1 results (high-sample r = −0.73, p = 0.004; intermediate-sample r = −0.71, p = 0.022; low-sample r = −0.84, p = 0.002). IS implementation exceeded 99% by 2019, as inter-lab SD’s reached their nadir value (~0.2). No other assessed variable correlated with time-dependent improvement in inter-lab reproducibility, including reference gene selection (ABL1 versus others), RQ-PCR reagent selection, assay type (FDA-approved, commercial, or laboratory-developed), or practice setting. IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in BCR::ABL1 quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.